Search
COVID-19-factsheet
basaglar-ca-pm
basaglar-ca-pmi
aggrenox consumer information
aptivus consumer information
atrovent product monograph
atrovent consumer information
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
UBC launches Canada's first graduate blockchain training path
UBC launches Canada's first graduate blockchain training path
Collaboration key to meeting consumers’ expectations for better animal welfare
Collaboration key to meeting consumers’ expectations for better animal welfare
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19